DJ Sativa Investments PLC Total Voting Rights. Exercise of Share Options.
RNS Number : 8183Y
Sativa Investments PLC
13 May 2019
Press Release 13(th) May 2019
The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
Sativa Investments PLC
("Sativa" or the "Company")
Exercise of Share Options and Total Voting Rights
Sativa Investments PLC (NEX: SATI), announces that it has allotted 6,666,667 new ordinary shares of 0.25 pence each in the Company ("Ordinary Shares") pursuant to the exercise of share options. Application has been made for the new Ordinary Shares to be admitted to trading on the NEX Exchange Growth Market ("Admission") and Admission is expected to become effective on 13(th) May 2019. The options have been exercised by JH Racing A&P LTD at a price of 2.25p per share and the gross proceeds of GBP150,000 receivable by the Company will be used for general working capital purposes. The new Ordinary Shares will rank pari passu in all respects with the existing Ordinary Shares of the Company.
These options were awarded to JH Racing A&P LTD in October 2018 through the surrender by Geremy Thomas of certain options granted to him (with an exercise price of 0.5p per share) on the Company's admission to trading on the NEX Exchange Growth Market. These options were granted as NTA (non-tax advantaged) options to JH Racing A&P LTD to fund sponsorship of the Sativa car in the Ginetta Junior Championship 2019 / 2020 season. The racing series is broadcast on ITV4 and reaches a combined audience of 19.4 million viewers and a trackside audience of 385,000. The car and team are heavily branded "Sativa Investments PLC" and were sponsored previously in Sativa's name at Geremy Thomas' personal expense.
Following Admission, the Company's issued share capital will comprise 516,566,667 Ordinary Shares, which number may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules. The Company does not hold any shares in treasury.
The Directors of the Company accept responsibility for the contents of this announcement.
- Ends -
For further information please contact:
Geremy Thomas Joseph Colliver Founder & Chief Executive Officer Chief Financial Officer Sativa Investments PLC Sativa Investments PLC +44 (0) 20 7971 1255 +44 (0) 20 7971 1255 firstname.lastname@example.org email@example.com NEX Exchange Corporate Adviser Guy Miller and Lucy Williams Peterhouse Capital Limited +44 (0) 20 7469 0930 firstname.lastname@example.org Financial PR and IR Abchurch Communications Julian Bosdet Abchurch Switchboard +44 (0) 20 7469 4630 SativaInvestments@abchurch-group.com www.abchurch-group.com
Notes to Editors
Sativa invests in well-placed ventures within the dynamic regulatory environment of the Medicinal Cannabis sector. The Company's pan-European, end-to-end, seed-to-consumer investment strategy focuses on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily permitted. Sativa has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment.
The Company's equity interest in an investment may range from a minority position, to a controlling interest, or to 100 per cent ownership. The ventures that Sativa acquires can either be public or private.
Sativa Investments has already made six investments to date, these being Canada-based and dual-listed emerging pharmaceutical company, Veritas Pharma Inc. ("Veritas Pharma" or "Veritas"), CSE-listed Toronto-based Pharma-Tech company Rapid Dose Therapeutics Inc. ("RDT"), which owns the patent-pending proprietary QuickStrip(TM) technology, UK-based CBD products provider George Botanicals Ltd (of which Sativa has 100 per cent ownership), PhytoVista Laboratories (of which Sativa also has 100 per cent ownership), a UK testing laboratory meeting the need for regulatory and batch testing of products such as CBD oil, a joint venture with Germany's Lexamed GmbH, and an option on a 7.53-acre development site in Wiltshire with the potential to build a glasshouse for growing raw cannabis for medicinal and CBD use.
Sativa is also focussed on researching and developing medicinal cannabis products by funding university research grants of medicinal cannabis through its Sativa Foundation.
The Company's Board and Medicinal Cannabis Advisory Board have a combined 60 years' industry experience, with significant pharmaceutical strength and experience and extensive contacts in the industry, which includes pharmacologist Sir Alasdair Breckenridge, who liaises with the Home Office and the Medicines and Healthcare products Regulatory Agency, which he has chaired, for the legalisation of medicinal cannabis in the UK Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development.
For more information on Sativa Investments, please visit: www.sativainvestments.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact email@example.com or visit www.rns.com.
(END) Dow Jones Newswires
May 13, 2019 05:19 ET (09:19 GMT)